MS patients not receiving medications to slow disease progression, research showsApril 17, 2007WINSTON-SALEM - Neurologists at Wake Forest University Baptist Medical Center have found that many patients diagnosed with multiple sclerosis (MS) are not taking or being prescribed drugs approved to treat the disease. "When we looked at patients who are being seen by family practitioners and by neurologists, we were surprised at the number of people who are not benefiting from drugs proven to help reduce the side effects of MS," said Cormac O'Donovan, M.D., a neurologist and co-investigator of the study. "Hopefully by educating physicians about the benefits of these drugs and beginning treatment early, we can slow the progression of this disease." O'Donovan's research was published this month by Biomed Central Medicine on their website at biomedcentral.com. O'Donovan and his team studied patient visits to family practitioners, neurologists or internists between 1998 and 2004 across the United States. There were an estimated 6.7 million MS patient visits to physicians during this time. Neurologists recorded the most patient visits (50.7 percent). About 62 percent of patients visiting neurologists and 92 percent seen by family practitioners/internists were not using immunomodulatory agents (IMAs), according to the research. Treatment with IMAs is known to reduce the frequency of relapses and slow disease progression. Six IMAs have been approved by the U.S. Federal Drug Administration (FDA) for use in treating MS. They are: interferon-1b (sold under the name Betaseron®), interferon-1a (Avonex®), glatiramer acetate (GA or Copaxone®), interferon-1a (Rebif®), mitoxantrone (Novantrone®) and natalizumab (Tysabri®). "Our study could not determine exactly why these FDA approved drugs were not being prescribed for the treatment of MS," O'Donovan said. "Some individuals may have mild symptoms at first and decide to defer treatment. Other factors may be that physicians are not as familiar with the newer drugs on the market and the risk-to-benefit ratio. Some patients may not even be aware of the pros and cons of IMAs or were advised by their physician that they did not meet the criteria for taking the drug. The increased use of IMAs by neurologists probably reflects greater awareness of the drugs' availability and their use by specialists who more often treat patients with MS. We need to spend some time looking further into the issue." MS is an inflammatory disease of the central nervous system. It is the second most common cause of neurological disability in young adults. The cause of MS is unknown but environmental factors and genetics are thought to contribute to the onset of the disease. Wake Forest University Baptist Medical Center |
|||||||||||||||||||||
| Related Neurologist Current Events and Neurologist News Articles Possible help in fight against muscle-wasting disease A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York. Alzheimer's researchers find high protein diet shrinks brain One of the many reasons to pick a low-calorie, low-fat diet rich in vegetables, fruits, and fish is that a host of epidemiological studies have suggested that such a diet may delay the onset or slow the progression of Alzheimer's disease (AD). Cost Effectiveness of Blood Pressure Device Evaluated A study conducted by the University of Rochester Medical Center (URMC) demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension. Rochester-led Parkinson's study pays off again, 2 decades later Parkinson disease progresses more slowly in patients who have higher levels of urate, a chemical that at very high level is associated with gout, scientists have found. Michigan hospital launches gene therapy study for Parkinson's disease A Michigan hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer. Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease? Rush University Medical Center is participating in a large-scale, multi-center clinical trial in the U.S. and Canada to determine whether a vitamin-like substance, in high doses, can slow the progression of Parkinson's disease, a neurodegenerative disorder that affects about one million people in the United States. Mayo Clinic identifies 2 genes as potential therapeutic targets for multiple sclerosis A Mayo Clinic study has found that two genes in mice were associated with good central nervous system repair in multiple sclerosis (MS). Fewer injection site reactions in patients using Avonex Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon® (interferon beta-1b), Copaxone® (glatiramer Acetate) or Rebif ® (interferon beta-1a). Seizure drug enhances sleep for women with hot flashes Gabapentin, a drug initially used to treat seizures, improves sleep quality in menopausal women with hot flashes, University of Rochester Medical Center researchers report online and in the September issue of the Journal of Women's Health. Is there long-term brain damage after bypass surgery? More evidence puts the blame on heart disease Brain scientists and cardiac surgeons at Johns Hopkins have evidence from 227 heart bypass surgery patients that long-term memory losses and cognitive problems they experience are due to the underlying coronary artery disease itself and not ill after-effects from having used a heart-lung machine. More Neurologist Current Events and Neurologist News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||